Biotech Scorecard
The top biotech stocks, tracked with live prices. Biotech is binary — a single trial readout or FDA decision can move a stock 30% overnight. This scorecard shows who's winning, who's struggling, and why.
Key insight: Of the 10 biotech stocks we track, — are up YTD and — are down.
Gene therapy (CRSP, ALNY) leads; mRNA post-COVID laggards (NVAX, EDIT) lag. Platform stories win; single-product stories fade.
Loading live prices…
| Company | Sector | Current Price | Change | YTD Return | Verdict |
|---|---|---|---|---|---|
| Moderna MRNA | mRNA | Loading… | — | +15.2% | Hold |
| BioNTech BNTX | mRNA | Loading… | — | +8.7% | Hold |
| Novavax NVAX | mRNA/Vaccines | Loading… | — | -22.4% | Avoid |
| CRISPR Therapeutics CRSP | Gene Therapy | Loading… | — | +31.5% | Buy |
| Editas Medicine EDIT | Gene Therapy | Loading… | — | -18.9% | Avoid |
| Vertex Pharmaceuticals VRTX | Rare Disease | Loading… | — | +12.3% | Buy |
| Regeneron REGN | Oncology/Immunology | Loading… | — | +6.8% | Hold |
| Gilead Sciences GILD | Oncology/Infectious Disease | Loading… | — | +4.1% | Hold |
| Biogen BIIB | Neuroscience | Loading… | — | -8.3% | Hold |
| Alnylam ALNY | RNAi/Rare Disease | Loading… | — | +19.7% | Buy |
The Thesis: What We're Watching
Winners
- CRISPR Therapeutics (CRSP): Casgevy approval (sickle cell) is a landmark. Next-gen CAR-T and solid tumor programs are the growth story.
- Vertex (VRTX): Cystic fibrosis monopoly with vanzacaftor expansion. Suzetrigine (non-opioid pain) is the next blockbuster. Casgevy royalty stream.
- Alnylam (ALNY): RNAi platform maturing. Nucapsiran (hypertension) could disrupt a $30B market. Cemdisiran PDUFA upcoming.
Losers
- Novavax (NVAX): Struggling to compete with mRNA platforms. Updated vaccine filings are a lifeline. Watch partnership with Sanofi.
- Editas (EDIT): EDIT-301 data underwhelming vs. Casgevy. Cash concerns. Strategic review ongoing.
Get scorecard updates by email
Live prices via Polygon.io. YTD returns are as of the most recent close. Verdicts reflect our editorial assessment based on fundamentals, pipeline, and sector conditions. Past performance does not guarantee future results. Nothing on this page is investment advice. Always do your own research and consult a licensed financial advisor.